Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:622-628
Published online before print December 27, 2007, doi: 10.1161/ATVBAHA.107.156059
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v28,pe154)
Right arrow All Versions of this Article:
28/4/622    most recent
ATVBAHA.107.156059v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cosentino, F.
Right arrow Articles by Lüscher, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cosentino, F.
Right arrow Articles by Lüscher, T. F.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:622.)
© 2008 American Heart Association, Inc.


Brief Reviews

Final Common Molecular Pathways of Aging and Cardiovascular Disease

Role of the p66Shc Protein

Francesco Cosentino; Pietro Francia; Giovanni G. Camici; Pier Giuseppe Pelicci; Massimo Volpe; Thomas F. Lüscher

From Cardiology and Cardiovascular Research (F.C., G.G.C., T.F.L.), University Hospital, Zürich, Institute of Physiology, University of Zürich, and Center for Integrative Human Physiology (ZIHP), Switzerland; Cardiology, 2nd Faculty of Medicine (F.C., P.F., M.V.), University "La Sapienza", Rome, Italy; Experimental Oncology (P.G.P.), European Institute of Oncology, Milan, Italy; and I.R.C.C.S. Neuromed (M.V.), Pozzilli (IS), Italy.

Correspondence to Thomas F. Luscher, MD, Cardiology & Cardiovascular Center, University Hospital, Ramistrasse, 100, CH-8091 Zürich, Switzerland. E-mail karlue{at}usz.unizh.ch

Oxidative stress affects the availability of key-regulators of vascular homeostasis and controls a number of signaling pathways relevant to myocardial and vascular disease. Reactive oxygen species are generated by different intracellular molecular pathways principally located in mitochondria. The notion that mice carrying a targeted mutation of the p66Shc gene display prolonged lifespan, reduced production of intracellular oxidants, and increased resistance to oxidative stress–induced apoptosis prompted a series of studies aimed at defining the biochemical function of p66Shc and its possible implication in cardiovascular diseases. Indeed, p66Shc–/– mice are protected against vascular, cardiac, and renal impairment attributable to hypercholesterolemia, aging, diabetes, and ischemia/reperfusion. The present review focuses on the biochemical and physiological function of the p66Shc adaptor protein as well as on the mechanisms linking p66Shc-associated generation of free radicals to the pathophysiology of aging and cardiovascular disease. On the whole, the evidence so far reported and here discussed supports the concept that pharmacological modulation of p66Shc expression and activity may be a novel and effective target for the treatment of atherosclerotic vascular disease as well as myocardial adaptation to hypertrophic, inflammatory and neuro-hormonal stimuli in the overloaded heart.

Mice carrying a targeted mutation of the p66Shc gene display reduced production of intracellular oxidants, increased resistance to oxidative stress-induced apoptosis, prolonged lifespan, and are protected against vascular, cardiac, and renal impairment attributable to hypercholesterolemia, aging, diabetes, and ischemia/reperfusion. The present review focuses on the biochemical function of the p66Shc adaptor protein as well as on the mechanisms linking p66Shc to the pathophysiology of aging and cardiovascular disease.


Key Words: p66Shc • aging • atherosclerosis • diabetes • energy metabolism




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
K. Boengler, R. Schulz, and G. Heusch
Loss of cardioprotection with ageing
Cardiovasc Res, July 15, 2009; 83(2): 247 - 261.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
V. Di Stefano, C. Cencioni, G. Zaccagnini, A. Magenta, M. C. Capogrossi, and F. Martelli
p66ShcA modulates oxidative stress and survival of endothelial progenitor cells in response to high glucose
Cardiovasc Res, June 1, 2009; 82(3): 421 - 429.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Sainz and M. Sata
When p66ShcA is away, mice EPCs sweetly play
Cardiovasc Res, June 1, 2009; 82(3): 388 - 389.
[Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
F. Cosentino, L. Rydén, P. Francia, and L. G. Mellbin
CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. J. Donato, I. Eskurza, K. L. Jablonski, L. B. Gano, G. L. Pierce, and D. R. Seals
Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans
J Appl Physiol, October 1, 2008; 105(4): 1359 - 1363.
[Abstract] [Full Text] [PDF]